Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86

巴克莱银行维持拜玛林制药(BMRN.US)买入评级，维持目标价86美元

moomoo资讯 · 11/01 15:31 · 评级/大行评级

Barclays analyst Gena Wang maintains $Biomarin Pharmaceutical (BMRN.US)$ with a buy rating, and maintains the target price at $86.

According to TipRanks data, the analyst has a success rate of 43.6% and a total average return of 7.6% over the past year.

AnalystRecentRatingAutoNews_206481_20241031_a508c810815b2be826b245345d88e9511c5d9ea0_1730489428810940_mm_en

Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:

BioMarin has delivered a strong quarter, with a slight increase in guidance for both revenue and earnings. Analysts believe that the value of the company's enzyme replacement therapy sector alone justifies the current share price. Furthermore, the impending clinical trials for BMN333 in early 2025 are seen as a potential major contributor to the company's value, both in maintaining market share in its current indications and potentially expanding into additional ones where Voxzogo is under investigation.
BioMarin's third quarter financial results exceeded expectations on both the top and bottom lines, with a slight increase in the fiscal 2024 guidance for all main metrics. Although Voxzogo's performance fell short of forecasts, this was balanced by outcomes from the company's enzyme replacement therapy business that surpassed expectations.
The firm identifies an appealing entry point at the current share levels for BioMarin, highlighting the company's robust base business and the prospect of significant operating margin growth in the coming years.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

巴克莱银行分析师Gena Wang维持$拜玛林制药 (BMRN.US)$买入评级，维持目标价86美元。

根据TipRanks数据显示，该分析师近一年总胜率为43.6%，总平均回报率为7.6%。

AnalystRecentRatingAutoNews_206481_20241031_a508c810815b2be826b245345d88e9511c5d9ea0_1730489428810940_mm_sc

此外，综合报道，$拜玛林制药 (BMRN.US)$近期主要分析师观点如下：

BioMarin发布了一个强劲的季度，营业收入和利润均有轻微增长。分析人士认为，公司的酶替代疗法板块的价值单独就足以证明当前股价的合理性。此外，2025年初即将进行的BMN333临床试验被视为对公司价值的潜在重要贡献，不仅可以在当前适应症中保持市场份额，还可能扩展至Voxzogo正在调查的其他适应症。
BioMarin的第三季度财务业绩超过了预期，各项主要指标的财年2024指引略有增加。尽管Voxzogo的业绩低于预期，但公司酶替代疗法业务的业绩却超出预期。
该公司确定了BioMarin目前股票水平的吸引入场点，突出了公司强大的基础业务以及未来几年中潜在的显著营业利润率增长前景。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86

Barclays Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $86

风险及免责提示

声明